SCHEMBL289208

SCHEMBL289208

CC(C)(C)P(c1cccn1-c1ccccc1)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
KDM4E B2RXH2 2/20 0.34
GAA P10253 2/20 0.34
ALDH1A1 P00352 3/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
MCL1 Q07820 1/20 0.33
NOTUM Q6P988 1/20 0.33
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
PKM P14618 1/20 0.33
COMT P21964 1/20 0.33
HTT P42858 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
FGFR1 P11362 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28612089 0.98 ATM (0.39) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL23047247 0.79 ATM (0.36) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL27928302 0.79 FGFR1 (0.44) KDM4EALDH1A1MEN1MAPTKMT2A
SCHEMBL20994199 0.75 KDM4E (0.43) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL17875026 0.74 ATM (0.48) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL20994183 0.73 ATM (0.40) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL27916646 0.73 ATM (0.40) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL29370031 0.73 GAA (0.51) GAAALDH1A1MEN1MAPTKMT2A
SCHEMBL6128412 0.72 CYP3A4 (0.44) ATMKDM4EGAAALDH1A1MEN1
SCHEMBL16351494 0.72 ABL1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427468-B2 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2025-06-04 EP claimed
US-12122788-B2 Process of making CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-22 US claimed
CN-115872998-B Preparation method of sildenafil and intermediate thereof 山东特珐曼药业有限公司 2024-09-20 CN claimed
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-12-14 US claimed
EP-4267591-A2 ORGANOMETALLIC COMPOUNDS Umicore AG & Co. KG (DE) 2023-11-01 EP claimed
CN-116802187-A Organometallic compounds 优米科尔股份公司及两合公司 2023-09-22 CN claimed
CN-115872998-A Preparation method of sildenafil and intermediate thereof 山东特珐曼药业有限公司 2023-03-31 CN claimed
WO-2022136049-A2 ORGANOMETALLIC COMPOUNDS UMICORE AG & CO. KG (DE) 2022-06-30 WO claimed
WO-2017112576-A1 METHODS FOR EXTERNAL BASE-FREE SUZUKI COUPLINGS DOW GLOBAL TECHNOLOGIES LLC (US) 2017-06-29 WO claimed
EP-2427468-B1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2017-06-14 EP claimed
US-20140051867-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2014-02-20 US claimed
US-20140051866-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2014-02-20 US claimed
EP-2621893-A1 PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES UCB Pharma GmbH (DE) 2013-08-07 EP claimed
WO-2013015456-A1 METHOD FOR PRODUCING BENZO[B]THIOPHENE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-31 WO claimed
US-8314232-B2 Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide GLAXOSMITHKLINE LLC (US) 2012-11-20 US claimed
US-20120116109-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-05-10 US claimed
WO-2012041986-A1 PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES UCB PHARMA GMBH (DE) 2012-04-05 WO claimed
EP-2427468-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-03-14 EP claimed
WO-2010128316-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2010-11-11 WO claimed
US-20100081805-A1 Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide EXELIXIS, INC. 2010-04-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS CFTR, SLC26A4, TMEM109 ATM 1176/4885KDM4E 3960/4885GAA 775/4885
US-20140051867-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND EIF2AK2, SARS1, MAVS ATM 3176/4885KDM4E 2210/4885GAA 257/4885
US-12122788-B2 Process of making CFTR modulators CFTR, SLC26A4, TMEM109 ATM 1176/4885KDM4E 3960/4885GAA 775/4885
US-20140051866-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND EIF2AK2, SARS1, MAVS ATM 3121/4885KDM4E 2217/4885GAA 247/4885
US-20120116109-A1 PREPARATION OF A METAL COMPLEX PDCD1LG2, CD274, PDCD2L ATM 1236/4885KDM4E 2792/4885GAA 4147/4885
US-20100081805-A1 Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide QDPR, CBR3, NQO2 ATM 2438/4885KDM4E 1032/4885GAA 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.